Dihydroergocryptine
Dihydroergocryptine Information

About Dihydroergocryptine

Dihydroergocryptine used in the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease

Indications

Dihydroergocryptine is primarily indicated in conditions like Cerebro-vascular insufficiency, Chronic venous insufficiency, Ischaemic heart disease, Migraine, Parkinsonism, and can also be given in adjunctive therapy as an alternative drug of choice in Behavioural disorders, Lactation inhibition, Peripheral vascular disease, Psychiatric disease, Raynaud's disease.

Contraindication

Dihydroergocryptine is contraindicated in conditions like Psychosis,Hypersensitivity to the drug.

Side Effects

The symptomatic adverse reactions produced by Dihydroergocryptine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea.

Warnings

There is evidence that exposure to Dihydroergotamine (a migraine drug) during pregnancy to give a teratogenic effect on the fetus. A teratogen is a substance that can cause birth defects. The likelihood and severity of the defects may be influenced by the level of exposure and the stage of pregnancy at which exposure occurred.

High Risk Groups

Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.